What's Happening?
CatalYm has commenced a Phase 2/3 clinical trial for Visugromab, an anti-GDF-15 antibody, aimed at treating cancer cachexia. The trial, known as VINCIT, will involve 518 patients with advanced cancers,
including non-small cell lung cancer and colorectal cancer. Cachexia, characterized by severe weight loss and muscle wasting, affects up to 70% of cancer patients and currently lacks approved treatments. The trial will assess Visugromab's efficacy in reversing cachexia symptoms and improving patient outcomes.
Why It's Important?
The development of Visugromab represents a significant advancement in addressing cancer cachexia, a condition that severely impacts patient quality of life and treatment efficacy. If successful, the trial could lead to the first approved pharmacological treatment for cachexia, offering hope to millions of cancer patients. This could also pave the way for new therapeutic approaches targeting GDF-15, potentially improving survival rates and treatment responses in cancer care.
